Aspirin is shown to reduce cancer risk
Side effects may not be worth benefits
Taking aspirin everyday may significantly reduce one's risk of cancer, according to two studies published on Tuesday. But experts are unsure if the benefits of taking aspirin daily are worth the potential side effects.
A study in Lancet found that "daily aspirin reduces the long-term risk of death due to cancer. However, the short-term effect is less certain, especially in women."
A second paper analyzed five randomized controlled studies in Britain and found that daily aspirin use reduced risk of metastatic cancer by 36 percent, the New York Times reported. The review of studies also found that daily aspirin intake reduced the risk of adenocarcinoma by 46 percent, the Times said.
"Because aspirin prevents the spread of cancers, it could potentially be used as a treatment," lead researcher of the Lancet study Dr. Peter M. Rothwell told the Philadelphia Inquirer. “In terms of prevention, anyone with a family history would be sensible to take aspirin," he told the Times.
Approximately 41 percent of Americans will be diagnosed with cancer at some point in their lives, the President's Cancer Panel reported in 2010. And in 2003 the World Health Organization predicted that global cancer rates will increase 50 percent by 2020.
Researchers think that environmental exposures and lifestyle choices are playing a major role in the soaring rates. Many people in industrialized nations have sedentary lifestyles and poor diets, and are also exposed to a range of carcinogens in their air, water and food. Earlier this month, a Swedish study found that ingesting a metal found in fertilizers might increase risk of breast cancer, MSNBC reported.
Because aspirin increases one's risk of stomach bleeding and strokes, researchers were hesitant to endorse the drug as a preventative agent.
“I’m not ready to say that everybody ought to take a baby aspirin a day to prevent cancer," Dr. Otis W. Brawley of the American Cancer Society told the Times.
This article originally appeared on GlobalPost.